The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect
Open accessAbstract
Importance of the field: Novel approaches are needed for patients with small cell lung cancer (SCLC), as response after relapse is poor with standard therapies. p53 gene mutations often occur, resulting in tumoral protein overexpression and allowing for their recognition by p53-specific cytotoxic T cells.Areas covered in this review: We describe the characteristics and manufacturing of INGN-225, a p53-modified adenovirus-tranduced dendritic cell vaccine, and review available data, to understand INGN-225's role in SCLC treatment. We discuss our pre-clinical, early Phase I/II, and ongoing randomized Phase II studies.What the reader will gain: INGN-225 was well tolerated (all toxicities ≤grade 2) in the Phase I/II trial (54 patients receiving at least 1 dose). Specific anti-p53 immune response was positive in 18/43 (41.8%) patients, with overall post-INGN-225 response observed in 17/33 (51.5%) and immune response data available in 29 (14 positive, 15 negative). Post-INGN-225 response was observed in 11/14 (78.6%) and 5/15 (33%) patients with positive and negative immune responses, respectively.Take home message: INGN-225 is safe, induces a significant immune response, and appears to sensitize SCLC to subsequent chemotherapy. Improvements in immune response induction and understanding the chemotherapy–immunotherapy synergism will determine INGN-225's future role as an anticancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In researches from Antonia’s and Chiappori’s group, a modified autologous dendritic cells expressing p53 peptides (DC-p53 (254)) was used as a p53 vaccine and applied in combination with chemotherapy in patients with small cell lung cancer (SCLC).595,596 Although objective clinical responses were observed in some patients”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [596]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R. L., Ward, E., Hao, Y., Xu, J., Murray, T., & Thun, M. J. (2008) · CA A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0010 · Cited by 10,184
Almand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C., Carbone, D. P., & Gabrilovich, D. I. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.678 · Cited by 1,340
Self-citationMechanisms and functional significance of tumour-induced dendritic-cell defects
Gabrilovich, D. I. (2004) · Nature reviews. Immunology · doi:10.1038/nri1498 · Cited by 1,022
Self-citationvon Pawel, J., Schiller, J. H., Shepherd, F. A., Fields, S. Z., Kleisbauer, J. P., Chrysson, N. G., Stewart, D. J., CLARK, P. I., Palmer, M., Depierre, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.658 · Cited by 968
Gene Therapy for Cancer: What Have We Done and Where Are We Going?
Roth, J. A., & Cristiano, R. J. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.1.21 · Cited by 636
Chapter 8 Use of Recombinant Adenovirus for Metabolic Engineering of Mammalian Cells
Becker, T. C., Noel, R. J., Coats, W. S., Gómèz‐Foix, A. M., Alam, T., Gerard, R. D., & Newgard, C. B. (1994) · Methods in cell biology · doi:10.1016/s0091-679x(08)60603-2 · Cited by 569
Mirza, N. N., Fishman, M., Fricke, I., Dunn, M. W., Neuger, A. M., Frost, T. J., Lush, R. M., Antonia, S. J., & Gabrilovich, D. I. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1690 · Cited by 566
Self-citationOzao-Choy, J., Ma, G., Kao, J., Wang, G. X., Meseck, M., Sung, M., Schwartz, M., Divino, C. M., Pan, P.-Y., & Chen, S.-H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4709 · Cited by 538
Mechanism of Immune Dysfunction in Cancer Mediated by Immature Gr-1+ Myeloid Cells
Gabrilovich, D. I., Velders, M. P., Sotomayor, E. M., & Kast, W. M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.9.5398 · Cited by 538
Self-citationBronte, V., Apolloni, E., Cabrelle, A., Ronca, R., Serafini, P., Zamboni, P., Restifo, N. P., & Zanovello, P. (2000) · Blood · doi:10.1182/blood.v96.12.3838 · Cited by 527
Research works printed but not linked: 15
- Chikamatsu K, 1999, Clin Cancer Res, 5, 1281
- van Oijen MG, 2000, Clin Cancer Res, 6, 2138
- Zwaveling S, 2002, Cancer Res, 62, 6187
- Parajuli P, 2001, Cancer Res, 61, 8227
- Eura M, 2000, Clin Cancer Res, 6, 979
- Brossart P, 1997, J Immunol, 158, 3270, 10.4049/jimmunol.158.7.3270 · DOI
- Dietz AB, 1998, Blood, 91, 392, 10.1182/blood.V91.2.392 · DOI
- 10.1089/hum.1997.8.11-1355 · DOI
- Nikitina EY, 2001, Clin Cancer Res, 7, 127
- D'Amico D, 1992, Oncogene, 7, 339
- Bodner SM, 1992, Oncogene, 7, 743
- Chiappori A, 2007, Proc Am Soc Clin Oncol, 25
- Pisarev V, 2003, Clin Cancer Res, 15, 6523
- Kusmartsev S, 2003, Cancer Res, 63, 4441
- Nimmanapalli R, 2001, Cancer Res, 61, 759
Cited by
Sorted by citations
Lung cancer immunotherapy: progress, pitfalls, and promises
Lahiri, A., Maji, A., Potdar, P. D., Singh, N., Parikh, P., Bisht, B., Mukherjee, A., & Paul, M. K. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01740-y · Cited by 1,102
Lung cancer: Biology and treatment options
Lemjabbar‐Alaoui, H., Hassan, O. U., Yang, Y., & Buchanan, P. C. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.08.002 · Cited by 1,067
Drugging p53 in cancer: one protein, many targets
Hassin, O., & Oren, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00571-8 · Cited by 771
Immune parameters affecting the efficacy of chemotherapeutic regimens
Zitvogel, L., Kepp, O., & Kroemer, G. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.223 · Cited by 686
Mutant p53 in cancer: from molecular mechanism to therapeutic modulation
Chen, X., Zhang, T., Su, W., Dou, Z., Zhao, D., Jin, X., Lei, H., Wang, J., Xie, X., Cheng, B., et al. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05408-1 · Cited by 494
Metadata
- Authors
- Chiappori, A. A., Soliman, H., Janssen, W. E., Antonia, S. J., & Gabrilovich, D. I.
- Affiliations
- University of South Florida (US)
- Moffitt Cancer Center (US)
- Corresponding author
- Chiappori, Alberto A
- Venue
- Expert Opinion on Biological Therapy
- Publisher
- Informa UK Limited
- Published
- 2010-04-26
- Volume
- 10
- Issue
- 6
- Pages
- 983-991
- ISSN
- 1471-2598 (ISSN-L)
- 1744-7682
- PMC
- PMC3146364
- OpenAlex
- W2144694610
- Cited by
- 126
- References
- 61
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 6 · 2023: 6 · 2022: 6 · 2021: 10 · 2020: 4 · 2019: 6 · 2018: 7 · 2017: 6 · 2016: 12 · 2015: 10 · 2014: 10 · 2013: 9 · 2012: 11
- FWCI
- 4.62
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Expert Opinion on Biological Therapy (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (K24CA128953, P50CA119997)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- dendritic cell vaccine, p53, small cell lung cancer, adenoviral vector, cancer immunotherapy, chemosensitization, vaccine safety, TP53 mutation
- MeSH terms
- Animals, Dendritic Cells, Humans, Immunotherapy, Lung Neoplasms, Randomized Controlled Trials as Topic, Tumor Suppressor Protein p53, Clinical Trials, Phase I as Topic, Clinical Trials, Phase II as Topic, Cancer Vaccines, Small Cell Lung Carcinoma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
